Callan JMB Reports $7M Operating Loss as SG&A Spikes, Secures $9.1M Chicago Contract
Callan JMB reported 2025 revenues of $5.7M, gross profit of $2.1M and an operating loss of $7.0M as SG&A rose to $8.6M on IPO-related and IT expenses. It extended a $9.1M emergency-preparedness contract in Chicago, launched a Pune cold-chain warehouse and inked a manufacturing oversight deal with Attune Biotech.
1. Financial Results
Callan JMB reported 2025 revenues of $5.7 million, down from $6.6 million a year earlier. Gross profit declined to $2.1 million and operating loss widened to $7.0 million as SG&A expenses rose to $8.6 million on IPO-related and increased IT costs. Cash and cash equivalents stood at $2.1 million at year-end.
2. Business Developments
The company extended its emergency preparedness contract with the City of Chicago through June 2026, adding $1.5 million and bringing its total value to $9.1 million. It also secured a five-year medical response contract with the Oregon Health Authority, launched a temperature-controlled warehouse in Pune, India, and signed a manufacturing oversight and commercialization agreement with Attune Biotech for its multi-asset pipeline.
3. Strategic Initiatives and Outlook
Callan JMB is expanding pharmaceutical logistics and specialty distribution, advancing U.S. onshoring initiatives and upgrading its Sentry Monitoring System to HTML5 for real-time temperature tracking. Management plans to strengthen core infrastructure, scale readiness capabilities and deepen government relationships to drive growth in healthcare and food logistics throughout 2026.